Previous 10 | Next 10 |
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced the appointment of Sir Keith Peters FRS as Chairman of the Company’s Scie...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that new translational data for BT5528 and preclinical data for tumor-targeted...
In 2018, the founder of Bicycle Therapeutics (NASDAQ: BCYC) , Sir Gregory Winter, was awarded the Nobel Prize in chemistry for his work in developing phage display (use of viruses that infect bacteria to connect proteins) to produce antibodies and peptides (small chains of amino acids) f...
The following slide deck was published by Bicycle Therapeutics plc in conjunction with this Read more ...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will participate in fireside chats at the following virtual inve...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that new translational research for second-generation Bicycle® Toxin Conjug...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that a poster describing the design of the ongoing Phase I/II trial of BT5528 wi...
- BT5528 optimized to have distinct physiochemical and in vivo properties thought to enable more favorable preclinical safety, efficacy profiles than those of an antibody drug conjugate Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differenti...
Bicycle Therapeutics (NASDAQ: BCYC ): Q1 GAAP EPS of -$0.63 misses by $0.55 . More news on: Bicycle Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
- Significant recent progress achieved across pipeline of innovative Bicycle ® - based therapies for oncology and beyond - Dosing underway in Phase I dose escalation of BT5528 in combination with nivolumab - Continued to strengthen corporate leadership with appointment of Ge...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
Bicycle Therapeutics plc Website:
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced the acceptance of four abstracts for poster presentation at the European So...
2024-06-10 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates ® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate,...